Literature DB >> 17636457

Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Amit Garg1, Joseph P Balthasar.   

Abstract

Although it is known that FcRn, the neonatal Fc-receptor, functions to protect immune gamma globulin (IgG) from elimination, the influence of FcRn on the tissue distribution of IgG has not been quantified. In the present work, a physiologically-based pharmacokinetic (PBPK) model has been developed to characterize and predict IgG disposition in plasma and in tissues. The model includes nine major compartments, connected in an anatomical manner, to represent tissues known to play a significant role in IgG disposition. Each tissue compartment was subdivided into vascular, endosomal and interstitial spaces. IgG transport between the blood and interstitial compartments may proceed by convection through paracellular pores in the vascular endothelium, or via FcRn-mediated transcytosis across vascular endosomal cells. The model was utilized to characterize plasma concentration-time data for 7E3, a monoclonal antiplatelet IgG1 antibody, in control and FcRn-knockout (KO) mice. These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 +/- 0.3 to 14.4 +/- 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 +/- 4.0 vs. 61.0 +/- 3.6 ml/d/kg). Based on model fitting to the 7E3 plasma concentration data, simulations were conducted to predict tissue concentrations of IgG in control and in KO mice, and the predictions were then tested by assessing 7E3 tissue distribution in KO mice and control mice. 7E3 was radiolabeled with Iodine-125 using chloramine T method, and (125)I-7E3 IgG was administered at a dose of 8 mg/kg to control and KO mice. At various time points, sub-groups of 3 mice were sacrificed, blood and tissue samples were collected, and radioactivity assessed by gamma counting. PBPK model performance was assessed by comparing model predictions with the observed data. The model accurately predicted 7E3 tissue concentrations, with mean predicted vs. observed AUC ratios of 1.04 +/- 0.2 and 0.86 +/- 0.3 in control and FcRn-KO mice. The PBPK model, which incorporates the influence of FcRn on IgG clearance and disposition, was found to provide accurate predictions of IgG tissue kinetics in control and FcRn-knockout mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636457     DOI: 10.1007/s10928-007-9065-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  54 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.

Authors:  Ryan J Hansen; Joseph P Balthasar
Journal:  Thromb Haemost       Date:  2002-12       Impact factor: 5.249

Review 3.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

4.  Testing for the equality of area under the curves when using destructive measurement techniques.

Authors:  A J Bailer
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

5.  Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy.

Authors:  H Zhu; R J Melder; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

Review 6.  FcRn: the MHC class I-related receptor that is more than an IgG transporter.

Authors:  V Ghetie; E S Ward
Journal:  Immunol Today       Date:  1997-12

7.  Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.

Authors:  E Sally Ward; Jinchun Zhou; Victor Ghetie; Raimund J Ober
Journal:  Int Immunol       Date:  2003-02       Impact factor: 4.823

8.  Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.

Authors:  V Ghetie; J G Hubbard; J K Kim; M F Tsen; Y Lee; E S Ward
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

9.  Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand.

Authors:  M Raghavan; M Y Chen; L N Gastinel; P J Bjorkman
Journal:  Immunity       Date:  1994-07       Impact factor: 31.745

10.  Intestinal transport of antibodies in the newborn rat.

Authors:  R Rodewald
Journal:  J Cell Biol       Date:  1973-07       Impact factor: 10.539

View more
  143 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

Review 2.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 3.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

Review 4.  Prediction of exposure-response relationships to support first-in-human study design.

Authors:  John P Gibbs
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

Review 5.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

6.  A new stochastic approach to multi-compartment pharmacokinetic models: probability of traveling route and distribution of residence time in linear and nonlinear systems.

Authors:  Liang Zhao; Na Li; Harry Yang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-17       Impact factor: 2.745

Review 7.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

8.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

9.  Impact of altered endogenous IgG on unspecific mAb clearance.

Authors:  Saskia Fuhrmann; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-24       Impact factor: 2.745

10.  A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.